Abstract
RSV immunoprophylaxis presents a challenge for MCOs. Despite its demonstrated ability to protect high-risk infants against serious RSV infection and to reduce morbidity, immunoprophylaxis with palivizumab incurs high costs that MCOs must grapple with every year. If MCOs, physicians, and professional organizations can agree on common guidelines for RSV management, then MCOs will be able to provide affordable treatment for those children at high risk.
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / therapeutic use*
-
Chemoprevention / standards*
-
Disease Management*
-
Home Care Services
-
Humans
-
Managed Care Programs*
-
Palivizumab
-
Pharmaceutical Services / standards
-
Practice Guidelines as Topic
-
Respiratory Syncytial Virus Infections / epidemiology*
-
Respiratory Syncytial Virus Infections / immunology
-
Respiratory Syncytial Virus Infections / prevention & control*
-
Risk Factors
-
Seasons*
-
United States / epidemiology
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antiviral Agents
-
Palivizumab